Replies to post #99932 on Biotech Values

[mcbio]

Re: ITMN CC

As previously mentioned for some reason I didn't hear the question on the 2nd generation PI so take this as a general comment. I've noticed Dan Welch being very closed lipped on events with both positive and negative outcomes so I would caution reading too much into that.

It comes up towards the very end of the CC just before the 37 minute mark. Dan Welch says a few different things but the ultimate point is effectively "no comment." I hear what you're saying but I don't see why he couldn't at least give general guidance that the Phase 1 trial would likely commence 4Q10 or 1Q11 or some other general timeline if the 2nd gen HCV PI were at least somewhat close to the clinic. To give no rough timeline whatsoever leads me to believe they are not close or there is some other issue. I could be wrong of course. We shall see.

[drbio45]

The CC had about as much excitement as a late September ballgame between the Baltimore Orioles and the Kansas City Royals.

The excitement of the call doesn't matter. All that matters is if pirfenidone gets approved in the EU.

if it gets approved it is a forty dollar stock if disapproved it is 4 dollars or less.

this is something like the mnta profile pre approval.

if they would have been told by the fda that they needed to run clinical trials it would have been a 4 dollar stock

[DewDiligence]

The [ITMN-191+SoC phase-2b] (boosted) trial actually sounds to have a more firm timetable for starting then past calls.

Not so, according to yesterday’s CC. The only timing change is that the trial start has been pushed back from 3Q10 to 4Q10.